CHAM
IOVA icon

Clear Harbor Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Clear Harbor Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,000
Closed -$66K – 374
2022
Q2 		$66K Buy
+6,000
New +$78.6K 0.01% 378

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Clear Harbor Asset Management's IOVA Position: Q2 2025 in Review

Clear Harbor Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 35,250 shares — an estimated $117K sold.

Clear Harbor Asset Management first reported a position in IOVA in Q2 2022 and held it in 6 quarters. The position peaked at $247K in Q2 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Clear Harbor Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Clear Harbor Asset Management sold 35,250 Iovance Biotherapeutics shares in Q2 2025, an estimated $117K.
  • Clear Harbor Asset Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • Clear Harbor Asset Management's Iovance Biotherapeutics position peaked at $247K in Q2 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Clear Harbor Asset Management's 13F filing for Q2 2025, filed 14 Jul 2025.